The Global Vaccine and Immunization Research Forum (GVIRF) is the central discussion platform of all research and innovation aspects related to the Immunization Agenda 2030 (IA2030), and specifically Strategic Priority 7, Research and Innovation. GVIRF is co-hosted by WHO, the US National Institute of Allergy and Infectious Diseases, and the Bill & Melinda Gates Foundation. Gathering together leading experts from public health, academia, government, civil society and private sector, the GVIRF is held every second year. The next meeting will be in Brazil in 2025.

Between meetings, GVIRF Webinars are exploring late-breaking developments in specific topics, such as mRNA vaccine technologies and malaria vaccines. 

The overall objective of the GVIRF is to serve as a forum to:

• Track progress and discuss obstacles related to priority vaccine research and development (R&D);
• Identify gaps, opportunities and actions for the R&D community in the areas of vaccines and immunization;
• Create opportunities for networking and collaboration among the vaccine R&D and immunization communities; and
• Review progress made towards the IA2030 SP7 research and development goal and strategic objectives

As endorsed by the IA2030 Leadership Council and the WHO Strategic Advisory Group of Experts (SAGE), research and innovation reporting for the IA2030 is conducted every two years, with emphasis on:

• Expanding capabilities of engagement with end-users,
• Enabling development of new vaccines,
• Accelerating development, licensing and update of vaccines, and
• Improving programme efficiencies and increasing coverage.

Past and upcoming GVIRF meeting and webinar announcements, agendas, videos, and presentations are available here.